Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

– Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit – – The filing application is based on data from the Phase III ...

Lupkynis is a medicine that is used for a specific kidney disease called lupus nephritis. Lupus nephritis is a kidney condition that affects people with systemic lupus erythematosus (SLE). SLE is an ...

Even in nonproliferative class 1-2 LN, glucocorticoid monotherapy may be insufficient to prevent long-term renal damage. Combination therapy should be considered. Patients with class 1-2 lupus ...

The histologic class of lupus nephritis was not predicted by proteinuria levels. The histologic class of lupus nephritis (LN) was not predicted by proteinuria levels, while a strong prediction of ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest. “The ...

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Brad Rovin, MD: ...

Roche said the European Commission approved its Gazyva treatment for patients with certain versions of lupus nephritis. The pharmaceutical company said that Gazyva, alongside mycophenolate mofetil, is ...